| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Bisphosphonates(BPs) agent with strong bone resorption inhibitory effect have been used for various enhanced bone-resorptive diseases. However, since BP-related osteonecrosis of the jaw (BRONJ), first reported in 2003, is increasing, with few effective strategies. BRONJ is exclusively associated with the use of nitrogen-containing BPs (NBPs). We previously reported that in mice, the non-NBP etidronate can reduce the inflammatory/necrotic effects of NBPs by inhibiting their intracellular entry and antagonize NBPs’ binding to bone hydroxyapatite absorption. We applied papers that the BRONJ 14 patients case and BRONJ patient of diabetes control bad case which tried to etidronate substitute replacement therapy of non-NBP.
|
